UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 1, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to___________ Commission File Number 0-18655 EXPONENT, INC. (Exact name of registrant as specified in its charter) | --- | --- | |----------------- ...

Financial Performance - Revenues for Q1 2022 increased by 10% to $128,478,000 compared to $116,481,000 in Q1 2021[85] - Net income decreased by 4% to $29,609,000 in Q1 2022, with diluted earnings per share at $0.56, down from $0.58 in Q1 2021[87] - Total operating income for Q1 2022 was $36,717,000, a 52.6% increase from $24,058,000 in Q1 2021[101] - EBITDA for Q1 2022 was $34,475,000, representing an increase from $31,753,000 in Q1 2021, with EBITDA as a percentage of revenues before reimbursements rising to 29.2% from 29.0%[118] - Net income for Q1 2022 was $29,609,000, a decrease from $30,848,000 in Q1 2021[119] Revenue Breakdown - Engineering and Other Scientific segment revenues rose by 11.8% to $104,615,000, accounting for 81.4% of total revenues[90] - Environmental and Health segment revenues increased by 4.3% to $23,863,000, representing 18.6% of total revenues[90] - The company experienced an 8% growth in revenues before reimbursements in Q1 2022, attributed to increased work from clients in various sectors[118] Expenses - Compensation and related expenses decreased by 7.8% to $68,757,000, constituting 53.5% of total revenues[94] - Other operating expenses rose by 5.9% to $8,165,000, making up 6.4% of total revenues[95] - Reimbursable expenses surged by 53.7% to $10,608,000, representing 8.3% of total revenues[99] - General and administrative expenses increased by 29.3% to $4,231,000, accounting for 3.3% of total revenues[100] Cash Flow and Assets - Net cash used in operating activities was $(6,352,000) in Q1 2022, compared to $1,285,000 in Q1 2021, indicating a significant decline in cash flow[109] - As of April 1, 2022, the company had cash and cash equivalents of $215,050,000, down from $297,687,000 at the end of 2021[109] - As of April 1, 2022, the company had net assets of approximately $12.0 million in British Pounds, $5.9 million in Chinese Yuan, and $6.8 million in Hong Kong Dollars[123] Tax and Other Income - The effective tax rate for Q1 2022 was 9.7%, a 12.1 percentage point increase from -2.4% in Q1 2021, with an excess tax benefit from stock-based awards decreasing to $6,040,000 from $8,782,000[106] - Other income, net, decreased by $10,278,000 in Q1 2022, representing a 164.4% decline compared to the previous year, primarily due to changes in the value of assets associated with the deferred compensation plan[105] - In Q1 2022, the company reported a decrease in deferred compensation expense of $10,278,000 compared to the same period last year, leading to a corresponding decrease in other income, net[104] Future Plans - The company plans to continue investing in capital expenditures and may use cash reserves for stock repurchases, dividends, or strategic acquisitions[113] Utilization Metrics - Billable hours increased by 5% to 374,000 in Q1 2022, with utilization rising to 77% from 76% in the same period last year[89]

Exponent, Inc. (NASDAQ:EXPO) Q1 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Joni Konstantelos - Investor Relations Catherine Corrigan - President and Chief Executive Officer Rich Schlenker - Executive Vice President and Chief Financial Officer Conference Call Participants Andrew Nicholas - William Blair Alexander Leach - Berenberg Capital Markets Tobey Sommer - Truist Securities Operator Good day and welcome to the Exponent, Inc. First Quarter of Fiscal Year 2022 Financial R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021. OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from ________ to _________. Commission File Number 0-18655 | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------- ...

Financial Data and Key Metrics Changes - For the full year 2021, net revenues grew 15%, and EBITDA margin expanded over 340 basis points compared to fiscal year 2020 [9] - Total revenues for Q4 2021 increased 9.9% to $113.5 million, while net revenues increased 7.2% to $104.3 million compared to Q4 2020 [27] - Net income for Q4 2021 decreased to $20.4 million or $0.38 per diluted share, compared to $21.8 million or $0.41 per diluted share in the prior year [28] - For the full year 2021, net income increased 22.5% to $101.2 million or $1.90 per diluted share [37] Business Line Data and Key Metrics Changes - Exponent's engineering and other scientific segment represented 81% of net revenues in Q4, increasing 8% in the quarter and 17% for the full year 2021 [22] - The environmental and health segment represented 19% of net revenues in Q4, with a 5% increase for both the quarter and full year 2021 [23] Market Data and Key Metrics Changes - Strong demand was noted across utilities, consumer electronics, consumer products, life sciences, and automotive sectors [10] - Proactive engagements in machine learning and user experience research remained strong, reflecting increasing demand for objective data [13] Company Strategy and Development Direction - The company is focused on expanding into new end markets, including pharmaceuticals and international arbitration [16] - Recruitment remains a top priority, with efforts to attract and retain talent being a key differentiator [21] - The proactive portfolio is roughly 50% of the business, with a focus on deepening client relationships and expanding service offerings [70] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strength of Exponent's market position and adaptability in the face of macroeconomic challenges [25] - The expectation for 2022 includes mid to high single-digit revenue growth and a decrease in EBITDA margin by 200 to 250 basis points compared to 2021 [45][46] Other Important Information - The company generated $124.6 million in cash from operations during fiscal 2021, with capital expenditures of $6.8 million [44] - Exponent ended 2021 with $297.7 million in cash and short-term investments [45] Q&A Session Summary Question: Can you walk through the margin guidance and its components? - Management indicated that the expected utilization drop would impact margins, with a significant portion of the decline attributed to returning expenses as the company resumes in-person activities [60] Question: What is the current status of court systems and their impact on throughput? - Management noted that court systems are operating at about 90% to 95% capacity compared to pre-pandemic levels, with expectations for further normalization [63] Question: How is the company differentiating itself in the competitive recruiting environment? - The company is focusing on providing a strong career path and breadth of experience to attract talent, alongside competitive compensation [65]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 1, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to___________ Commission File Number 0-18655 EXPONENT, INC. (Exact name of registrant as specified in its charter) DELAWARE 77-0218904 (State or ...

Exponent, Inc. (NASDAQ:EXPO) Q3 2021 Results Conference Call October 28, 2021 4:30 PM ET Company Participants Joni Konstantelos - Investor Relations Catherine Corrigan - President and Chief Executive Officer Rich Schlenker - Executive Vice President and Chief Financial Officer. Conference Call Participants Tobey Sommer - Truist Securities Andrew Nicholas - William Blair Sam England - Berenberg Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Ti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 2, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to___________ Commission File Number 0-18655 EXPONENT, INC. 94025 (ZipCode) (Exact name of registrant as specified in its charter) DELAWARE 77-0218 ...

Exponent, Inc. (NASDAQ:EXPO) Q1 2021 Earnings Conference Call April 29, 2021 4:30 PM ET Company Participants Whitney Kukulka - Investor Relations Dr. Catherine Corrigan - President and CEO Rich Schlenker - Executive Vice President and CFO Conference Call Participants Tobey Sommer - Truist Securities Andrew Nicholas - William Blair Marc Riddick - Sidoti Operator Good day. And welcome to the Exponent First Quarter and Fiscal Year 2021 Earnings Call. Today’s conference is being recorded. At this time, I would ...

Exponent, Inc. (NASDAQ:EXPO) Q4 2020 Earnings Conference Call February 4, 2021 4:30 PM ET Company Participants Whitney Kukulka - IR Dr. Catherine Corrigan - President and CEO Rich Schlenker - EVP and CFO Conference Call Participants Tobey Sommer - Truist Andrew Nicholas - William Blair Sam England - Berenberg Marc Riddick - Sidoti Operator Good day, and welcome to the Exponent Fourth Quarter and Fiscal Year 2020 Earnings Call. Today's conference is being recorded. At this time, I would like to turn the conf ...